Arthur Hayes turns up the ‘risk dial’ on these seven DeSci tokens
Maelstrom fund has "aped into" a number of Decentralised Science tokens.
Arthur Hayes wants investors to get as risky as they possibly can.
“I will encourage the risk-takers at the fund to turn the risk dial” to degen, or high-risk trading, the chief investment officer at Maelstrom fund wrote in his latest blog post.
For Hayes, that means pouring money into a smallish sector of crypto: decentralised science, or DeSci for short. The term refers to tokens that target systemic inefficiencies in traditional scientific processes, including funding, limited access to longevity investments, and IP concerns.
The sector is worth some $2.2 billion.
Hayes said that crypto investors are overlooking DeSci — and his firm has piled into the burgeoning decentralised science industry, Hayes wrote on January 6. He added that his fund loves undervalued tokens.
“DeSci is one of the few truly new narratives in the space that many market participants have yet to hear of,” said Lukas Ruppert, an analyst at Maelstrom.
But that looks primed to change.
Research firm Kaito revealed that DeSci’s mindshare soared a whopping 2,600% in 2024, outpacing even the highly hyped up AI, and crypto’s most daring sector, memecoins.
Maelstrom allocated assets to seven DeSci tokens, including BIO — which accounts for half of the entire sector’s valuation — PSY, a project that tokenises intellectual property on psychedelics, and CRYO, a cryopreservation research project. The others are BIO, VITA, ATH, GROW, and NEURON.
Users who buy these tokens can tap into the underlying companies’ platforms for funding, voting on governance proposals, and early access into commercialisation of products.
Hayes maintained his firm’s $200,000 price target for Bitcoin, and laid out when he thinks the asset will peak.
Degen Desci
DeSci tokens are an asymmetrical bet.
Ruppert’s thesis lies in the small number of DeSci tokens that exist right now.
“There will only ever be so many OG DeSci blue chips,” he wrote. “Based on this unique dynamic, small cap inaugural BioDAOs offer the greatest upside potential.”
Pedro Solimano is a Markets Correspondent at DL News. Got a tip? Email him at psolimano@dlnews.com.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
816,760% Profit Triggers Epic Ethereum Whale Awakening After 9 Years of Silence
Florida Senator Embraces Bitcoin Strategic Reserve
Florida Sen. Joe Gruters backs Bitcoin Strategic Reserve, calling state "open for business" on crypto.A Lawmaker Champions Bitcoin in FloridaWhat the Bitcoin Strategic Reserve Could MeanFlorida’s Crypto-Friendly Reputation

Vietnam Legalizes Crypto Under New Digital Tech Law
Vietnam approves landmark Law on Digital Technology, legalizing crypto assets from Jan 1, 2026.Legal Recognition of Crypto AssetsA Regulated Framework Comes into ForceBoosting Tech EcosystemWhy It MattersWhat to Expect Next

Presale Investors Target Early Bird Opportunity On Nexchain To Beat XRP And ADA
Nexchain leads 2025’s crypto presale scene with AI blockchain tech, $4.3M raised, and 429% ROI potential. Discover why it's the top presale crypto to buy now.Nexchain: AI Blockchain Leading The Crypto Presale MarketXRP: Legal Battle Keeps Traders On EdgeADA: Whale Accumulation Signals Long-Term ConfidenceFinal Words: Nexchain Dominates The Crypto Presale List

Trending news
MoreCrypto prices
More








